Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Tatva Chintan Pharma Chem Ltd

| Quarterly Financial Results Q3 FY 2025–26

BULLISH SENTIMENT

Report Source

⬤21st Jan 26

Summary : Tatva Chintan Pharma Chem Limited reported robust financial growth for Q3 and 9M FY26, with significant increases in revenue and profit, and an unmodified audit opinion.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Cost of materials consumed: Q3 FY26: INR 696.13 million.
  2. Consolidated Employee benefits expense: Q3 FY26: INR 168.24 million.
  3. Standalone Cost of materials consumed: Q3 FY26: INR 696.13 million.
  4. Standalone Employee benefits expense: Q3 FY26: INR 168.24 million.
  5. Consolidated Revenue from operations: Q3 FY26: INR 1,313.34 million, 9M FY26: INR 3,717.14 million.
  6. Standalone Revenue from operations: Q3 FY26: INR 1,385.88 million, 9M FY26: INR 3,636.31 million.
  7. Paid-up equity share capital: INR 233.92 million.
  8. Consolidated Other equity (excluding revaluation reserve): INR 7,154.32 million (as of 31.03.2025).
  9. Standalone Other equity (excluding revaluation reserve): INR 6,979.20 million (as of 31.03.2025).
  10. Both standalone and consolidated results presented.
  11. Consolidated includes Tatva Chintan USA Inc. and Tatva Chintan Europe B.V. as wholly-owned subsidiaries.

Corporate Overview

  1. India (Ankleshwar, Dahej, Vadodara), USA, Europe.
  2. Assessing impact of new Labour Codes on employee benefits.
  3. Specialty chemicals manufacturing and sales.
  4. Formal and compliant with regulatory requirements.
  5. Specialty chemicals.

Risk Factors

  1. New Labour Codes impact employee benefits.
  2. Monitoring finalisation of government rules.
  3. Potential for future regulatory changes.
  4. Global economic conditions may affect operations.

Key Drivers

  1. Strong revenue growth across periods.
  2. Significant increase in quarterly profit.
  3. Unmodified audit opinion received.
  4. Global subsidiary operations expanding reach.

Auditor’s Report

  1. Unmodified opinion for financial results.
  2. No material misstatements identified during review.

Board Commentary

  1. Impact of Labour Codes on employee benefits.
  2. Compliance with SEBI Listing Regulations and Companies Act.

Corporate Governance

  1. Audit Committee reviewed and recommended financial results.

Management Discussion & Analysis

Future Strategy

  1. Monitoring Labour Code finalisation for compliance.

Performance Drivers

  1. Strong revenue and profit growth.

Risk Control Measures

  1. Monitoring government clarifications on Labour Codes.

Critical Risks

  1. Impact of new Labour Codes on employee benefits.
Tatva Chintan Pharma Chem Ltd (TATVA) Quarterly Report Analysis & Insights | Dhanarthi